Since 1992 Alexion Pharmaceuticals has been a big hitter in the orphan drugs industry. despite having just one approved product on the market, Alexion’s portfolio stretches across from uremic diseases, aHUS, to neurological disorders, and acute antibody-mediated rejection. and this is all on the shoulder of what is arguably the most famous rare disease treatment in the world: Soliris.
Famous for being the most expensive drug in the world, Soliris forms the foundation for alexion’s success, as well as it’s future revenue. With a 6th orphan drug designation being awarded in the last month there would seem to be no reduction in the potential this blockbuster drug has to earn Alexion billions.